La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Avicanna Bilan de santé

Santé financière contrôle des critères 2/6

Avicanna possède un total de capitaux propres de CA$8.0M et une dette totale de CA$1.4M, ce qui porte son ratio d'endettement à 17.4%. Son actif total et son passif total sont CA$19.4M et de CA$11.4M.

Informations clés

17.4%

Ratio d'endettement

CA$1.39m

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	CA$488.21k
Fonds propres	CA$7.96m
Total du passif	CA$11.41m
Total des actifs	CA$19.37m

Mises à jour récentes de la santé financière

Here's Why Avicanna (TSE:AVCN) Can Afford Some Debt

Apr 18

Recent updates

Why Investors Shouldn't Be Surprised By Avicanna Inc.'s (TSE:AVCN) 35% Share Price Surge

Aug 28

Market Participants Recognise Avicanna Inc.'s (TSE:AVCN) Revenues Pushing Shares 79% Higher

Jul 11

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de AVCN ( CA$6.7M ) ne couvrent pas ses passifs à court terme ( CA$9.6M ).

Passif à long terme: Les actifs à court terme de AVCN ( CA$6.7M ) dépassent ses passifs à long terme ( CA$1.8M ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: Le ratio dette nette/capitaux propres de AVCN ( 11.3% ) est considéré comme satisfaisant.

Réduire la dette: Le ratio d'endettement de AVCN est passé de 4.8% à 17.4% au cours des 5 dernières années.

Bilan

Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: AVCN dispose de moins d'un an de piste de trésorerie sur la base de son flux de trésorerie disponible actuel.

Prévisions de trésorerie: AVCN dispose de moins d'un an de marge de trésorerie si le flux de trésorerie disponible continue de croître à un taux historique de 23.5 % chaque année.

Avicanna Bilan de santé

Santé financière contrôle des critères 2/6

Informations clés

Mises à jour récentes de la santé financière

Here's Why Avicanna (TSE:AVCN) Can Afford Some Debt

Recent updates

Why Investors Shouldn't Be Surprised By Avicanna Inc.'s (TSE:AVCN) 35% Share Price Surge

New major risk - Financial position

Second quarter 2024 earnings released: CA$0.021 loss per share (vs CA$0.021 loss in 2Q 2023)

New major risk - Share price stability

Market Participants Recognise Avicanna Inc.'s (TSE:AVCN) Revenues Pushing Shares 79% Higher

Member of Business Advisory Board recently bought CA$60k worth of stock

Avicanna Announces United States Patent and Trademark Office Issuance of Patent SEDDS Technology

Avicanna Inc., Annual General Meeting, Jul 10, 2024

Insider recently bought CA$251k worth of stock

It's Down 35% But Avicanna Inc. (TSE:AVCN) Could Be Riskier Than It Looks

First quarter 2024 earnings released: CA$0.011 loss per share (vs CA$0.033 loss in 1Q 2023)

Avicanna Inc. Announces Results of Study in Patients with Epidermolysis Bullosa

Avicanna Inc. announced that it has received CAD 2.125584 million in funding

Avicanna Inc. Announces Completion of Topical Gel Observational Real-World Evidence Study

Shareholders Should Be Pleased With Avicanna Inc.'s (TSE:AVCN) Price

Full year 2023 earnings released: CA$0.10 loss per share (vs CA$0.25 loss in FY 2022)

Avicanna Inc Announces the Canadian Launch of 10% CBD (THC Free) Proprietary Formulation

Avicanna Inc. to Report Fiscal Year 2023 Results on Apr 01, 2024

Avicanna Inc. Obtains Its First Indication-Specific Drug Registration with Trunerox

Avicanna Inc. announced that it has received CAD 0.888128 million in funding

Less than half of directors are independent

New major risk - Financial position

Third quarter 2023 earnings released: CA$0.016 loss per share (vs CA$0.048 loss in 3Q 2022)

Avicanna Announces Appointment of Paul Fornazzari to Board of Directors

Avicanna Inc. to Report Q3, 2023 Results on Nov 14, 2023

Avicanna Inc. Provides Update on the Successful Launch of MyMedi.ca

Avicanna Inc. Announces Retirement of Chandra Panchal, PhD from the Board of Directors

New minor risk - Share price stability

Second quarter 2023 earnings released: CA$0.021 loss per share (vs CA$0.08 loss in 2Q 2022)

Avicanna Inc. announced that it has received CAD 1.455 million in funding

Avicanna Inc. (TSX:AVCN) completed the acquisition of Medical Cannabis by Shoppers Drug Mart Inc from Shoppers Drug Mart Inc.

New minor risk - Share price stability

Avicanna Inc. (TSX:AVCN) entered into definitive Asset Purchase Agreement to acquire Medical Cannabis by Shoppers Drug Mart Inc from Shoppers Drug Mart Inc. for CAD 2.6 million.

First quarter 2023 earnings released: CA$0.033 loss per share (vs CA$0.02 loss in 1Q 2022)

Here's Why Avicanna (TSE:AVCN) Can Afford Some Debt

Insider recently bought CA$58k worth of stock

Insider recently bought CA$130k worth of stock

Avicanna LATAM S.A.S. Announces Step Down of Lucas Nosiglia as President, Effective January 31, 2023

Avicanna Inc. announced that it has received CAD 1.769097 million in funding

Avicanna and Santé Cannabis Initiate Real-World Evidence Study on Musculoskeletal Pain and Inflammation with the Rho Phytotm Cbg Transdermal Gel Topical Product

Avicanna Inc. Commercializes ‘Influid’, a Proprietary Water-soluble technology in the Canadian Market

Insider recently bought CA$539k worth of stock

Third quarter 2022 earnings released: CA$0.048 loss per share (vs CA$0.065 loss in 3Q 2021)

Third quarter 2022 earnings released: CA$0.048 loss per share (vs CA$0.065 loss in 3Q 2021)

Avicanna Inc. announced that it has received CAD 0.626763 million in funding

Avicanna Files Complete Patent Specifications Relating to A Novel Cannabinoid Formulation for Reducing Incidence of Seizures and Sudden Unexpected Death in Epilepsy

Avicanna Introduces a New Medical Cannabis Education Online Portal, "Avicenna Academy" for Health Care Professionals

Assad Kazeminy Retires as Director of Avicanna Inc

Avicanna Inc. announced that it has received CAD 2.782302 million in funding

Second quarter 2022 earnings released: CA$0.08 loss per share (vs CA$0.067 loss in 2Q 2021)

Avicanna Inc., Annual General Meeting, Aug 31, 2022

An unknown buyer acquired 63 percent stake in Sativa Nativa S.A.S. from Avicanna Inc. (TSX:AVCN) for CAD 0.81 million.

Forecast to breakeven in 2024

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Avicanna Inc. Announces Chief Financial Officer Changes

Avicanna Inc. announced that it has received CAD 1.473826 million in funding from Ei.Ventures, Inc.

Price target decreased to CA$0.70

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Avicanna Inc. announced that it has received CAD 2.523568 million in funding

Avicanna Inc. Provides Consolidated Revenue Guidance for the Fourth Quarter, Full Year 2021 and Full Year 2022

Avicanna Inc. announced that it expects to receive CAD 1.3008 million in funding

Forecast to breakeven in 2024

Avicanna Inc. Launches Its Clinically Backed CBD Derma-Cosmetics Brand, Pura H&W, in the United States in Partnership with Red White and Bloom

Avicanna and Harrington Wellness Launch Re+Play™ Branded Cbd Topicals Products in Canada

Avicanna Inc. Files Patent to Protect its Advanced Oral Cannabinoid Platform and its Applications for Neurological Diseases

Third quarter 2021 earnings released: CA$0.065 loss per share (vs CA$0.25 loss in 3Q 2020)

Insider recently bought CA$85k worth of stock

Avicanna Files US Patent Application for a Novel Cannabinoid Formulation in Reducing Incidence of Seizures and Sudden Unexpected Death in Epilepsy

Second quarter 2021 earnings released: CA$0.067 loss per share (vs CA$0.31 loss in 2Q 2020)

Less than half of directors are independent

Avicanna Inc. announced that it has received CAD 2.118 million in funding

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan